SHARE FOCUS: Dermapharm falls to 18-month low after weak numbers

FRANKFURT (dpa-AFX) – Dermapharm’s shares reacted to the pharmaceutical manufacturer’s disappointing business figures with massive losses on Wednesday. They lost almost nine percent at times and reached their lowest level since November 2020 at EUR 46.94. In the late morning, the paper was still 6.5 percent lower at EUR 48.16. Together with Verbio, they were the weakest stock in the SDAX small-cap index.

Dermapharm had a weak start to the year and clearly missed market expectations, judged analyst Daniel Grigat from the analysis company Stifel with regard to the development of sales and the operating result (Ebitda). This is likely to have a negative impact on investors, even if the growth in operating earnings was more dynamic than the company itself had announced. However, he remains optimistic about the stock and believes it is possible that the company’s goals will be set higher at some point.

Alexander Thiel from the analysis firm Jefferies attested the drug manufacturer a mixed first quarter. Dermapharm got off to a solid, but uninspiring start to the year. The confirmed annual targets underscored the company’s conservative outlook.

In autumn 2020, the newly announced cooperation with Biontech in the production of the corona vaccine had driven the good run of the share, and in 2021 the company had benefited greatly from it. But the euphoria is now gone. At the beginning of January, the price reached the end of the road: the price has now fallen by almost half from the record price of almost 92 euros. The price losses in the current year now add up to around 45 percent./edh/tih/jha/